Search for content, post, videos

BioArctic receives new drug substance patent in the US

Gunilla Osswald
BioArctic has announced that the US Patent and Trademark Office (USPTO) has granted a new drug substance patent for the antibody ABBV-0805, invented by BioArctic as a potential treatment of Parkinson's disease. The patent will take effect on May 24, 2022, and expire in 2041, with the possibility
Already a subscriber Login

You have read all your free articles, to continue reading subscribe to read the rest of this content.